TNFAIP2 and cancer: After genotyping the TNFAIP2 rs8126 polymorphism in 1077 HNSCC patients and 1073 cancer-free controls in a non-Hispanic White population, Liu et al found that, compared with the rs8126 TT genotype, the variant C allele were associated with increased HNSCC risk in an allele dose-response manner (OR = 1.48, 95% CI = 1.06–2.05 for the CC genotype, respectively; Ptrend  = 0.009) [15].